We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi’s Dupixent significantly reduced severe asthma attacks and rapidly improved lung function in children aged six to 11 years old with uncontrolled moderate-to-severe asthma, according to detailed results from a Phase III trial.